0
Startups & Venture·November 10, 2026·1 min read

Proximal Ventures raises debut fund to back startups bringing AI to drug development

Share

A $27.5M debut fund focused on AI in pharma is another data point that capital is shifting from horizontal AI tools to domain-specific wedges like drug development. Founders in biotech-adjacent AI should lean into deep integration with pharma workflows, not generic “platform” pitches.

Startups & Venture

S-1: Nvidia plans to invest about $10B in Anthropic after its IPO, or ~10% of the new cash Anthropic is expected to raise this month, including in the IPO

A planned ~$10B check into Anthropic cements the flywheel: Nvidia funds the model layer that in turn drives demand for its compute. If you’re a model or infra startup, assume tighter strategic coupling between chip providers and frontier labs—distribution and pricing may hinge on which ecosystem you align with.